Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK.
Holmusk Technologies, New York, NY, USA.
Lancet Psychiatry. 2023 May;10(5):334-341. doi: 10.1016/S2215-0366(23)00066-4. Epub 2023 Mar 23.
Identifying patients most at risk of psychiatric hospitalisation is crucial to improving service provision and patient outcomes. Existing predictors focus on specific clinical scenarios and are not validated with real-world data, limiting their translational potential. This study aimed to determine whether early trajectories of Clinical Global Impression Severity are predictors of 6 month risk of hospitalisation.
This retrospective cohort study used data from the NeuroBlu database, an electronic health records network from 25 US mental health-care providers. Patients with an ICD-9 or ICD-10 code of major depressive disorder, bipolar disorder, generalised anxiety disorder, post-traumatic stress disorder, schizophrenia or schizoaffective disorder, ADHD, or personality disorder were included. Using this cohort, we assessed whether clinical severity and instability (operationalised using Clinical Global Impression Severity measurements) during a 2-month period were predictors of psychiatric hospitalisation within the next 6 months.
36 914 patients were included (mean age 29·7 years [SD 17·5]; 21 156 [57·3%] female, 15 748 [42·7%] male; 20 559 [55·7%] White, 4842 [13·1%] Black or African American, 286 [0·8%] Native Hawaiian or other Pacific Islander, 300 [0·8%] Asian, 139 [0·4%] American Indian or Alaska Native, 524 (1·4%) other or mixed race, and 10 264 [27·8%] of unknown race). Clinical severity and instability were independent predictors of risk of hospitalisation (adjusted hazard ratio [HR] 1·09, 95% CI 1·07-1·10 for every SD increase in instability; 1·11, 1·09-1·12 for every SD increase in severity; p<0·0001 for both). These associations were consistent across all diagnoses, age groups, and in both males and females, as well as in several robustness analyses, including when clinical severity and clinical instability were based on the Patient Health Questionnaire-9 rather than Clinical Global Impression Severity measurements. Patients in the top half of the cohort for both clinical severity and instability were at an increased risk of hospitalisation compared with those in the bottom half along both dimensions (HR 1·45, 95% CI 1·39-1·52; p<0·0001).
Clinical instability and severity are independent predictors of future risk of hospitalisation, across diagnoses, age groups, and in both males and females. These findings could help clinicians make prognoses and screen patients who are most likely to benefit from intensive interventions, as well as help health-care providers plan service provisions by adding additional detail to risk prediction tools that incorporate other risk factors.
National Institute for Health and Care Research, National Institute for Health and Care Research Oxford Health Biomedical Research Centre, Medical Research Council, Academy of Medical Sciences, and Holmusk.
识别最有可能住院的精神病患者对于改善服务提供和患者预后至关重要。现有的预测因素侧重于特定的临床情况,并且没有使用真实世界的数据进行验证,限制了其转化潜力。本研究旨在确定临床总体印象严重程度的早期轨迹是否可以预测 6 个月的住院风险。
这是一项回顾性队列研究,使用了来自 25 家美国精神卫生保健提供者的电子健康记录网络 NeuroBlu 数据库中的数据。纳入患有 ICD-9 或 ICD-10 编码的重性抑郁障碍、双相情感障碍、广泛性焦虑障碍、创伤后应激障碍、精神分裂症或分裂情感障碍、注意缺陷多动障碍或人格障碍的患者。使用该队列,我们评估了在接下来的 6 个月内,在 2 个月期间的临床严重程度和不稳定性(使用临床总体印象严重程度测量来操作)是否可以预测精神病住院。
共纳入 36914 名患者(平均年龄 29.7 岁[标准差 17.5];21156 名[57.3%]女性,15748 名[42.7%]男性;20559 名[55.7%]白人,4842 名[13.1%]黑人或非裔美国人,286 名[0.8%]夏威夷原住民或其他太平洋岛民,300 名[0.8%]亚洲人,139 名[0.4%]美洲印第安人或阿拉斯加原住民,524 名[1.4%]其他或混合种族,10264 名[27.8%]种族不详)。临床严重程度和不稳定性是住院风险的独立预测因素(每增加一个标准差的不稳定性,调整后的危险比[HR]为 1.09[95%CI 1.07-1.10];每增加一个标准差的严重程度,HR 为 1.11[1.09-1.12];均<0.0001)。这些关联在所有诊断、年龄组以及男性和女性中均一致,并且在几项稳健性分析中也是如此,包括当临床严重程度和临床不稳定性基于患者健康问卷-9 而不是临床总体印象严重程度测量时。与严重程度和不稳定性均处于队列下半部分的患者相比,严重程度和不稳定性均处于队列上半部分的患者住院的风险更高(HR 1.45[95%CI 1.39-1.52];<0.0001)。
临床不稳定性和严重程度是未来住院风险的独立预测因素,适用于各种诊断、年龄组以及男性和女性。这些发现可以帮助临床医生进行预后判断,并对最有可能从强化干预中受益的患者进行筛查,同时还可以帮助医疗保健提供者通过在纳入其他风险因素的风险预测工具中添加其他详细信息来规划服务提供。
英国国家卫生与保健研究院、英国国家卫生与保健研究院牛津健康生物医学研究中心、医学研究理事会、英国皇家医学科学院和 Holmusk。